Эффективность и переносимость сульфасалазина при ревматических заболеваниях
https://doi.org/10.14412/1995-4484-2005-617
Аннотация
Список литературы
1. <div><p>Насонова ВА., Насонов ЕЛ. Рациональная фармакотерапия ревматических заболеваний. М., Литтерра, 2003.</p><p>Сигидин Я.А., Г.ВЛукина. Ревматоидный артрит. М., 2001.</p><p>American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 Update. Arthr. Rheum., 2002, 46, 328-346.</p><p>Azulfidine, EN-Tabs. In: Physicians Desk Reference, Medical Economics Company, 52nd ed. Montvale, NJ, 1998, 2239.</p><p>Boers М., 4’rhoeven A.C., Marcusse H.M. et al. Randomised comparison of combinet step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet, 1997,350, 1568-1573.</p><p>Box S.A., Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br. J. Rheumatol., 1997, 36, 382.</p><p>Brandt J., Buss B., SieperJ., Braun J. Efficacy of treatment with sulphasalazine versus azathioprine in ankylosing spondylitis. J. Rheumatol., 2000, 27, suppl. 59, I82-1S4.</p><p>Calin A., Taurog J.D. Spondylarthritides. Oxford University Press, 1998.</p><p>Clegg D.O., Reda D.J., Mejias E. et al. Comparison of sulfasalazine and placebo for the treatment of psoriatic arthritis and cutaneous psoriasis. Arthr. Rheum., 1996, 39, 2013-2020.</p><p>Clegg D.O., Reda D.J., Wfeisman M.N. et al. Comparison of sulphasalazine and placebo in the treatment of reactive arthritis (Reiter s syndrome). A Department of feterans Affairs Cooperative study. Arthr. Rheum., 1996, 39, 2021-2027.</p><p>Clegg L.J, Reda D.J, Abdellatif M. Comparison of sulphasalazine for the treatment and placebo of axial and peripher- ial articular manifestations of the seronegative spondyloarthropathies. Arthr. Rheum., 1999, 42, 2325-2329.</p><p>Combe B., Goupill P., Kunntz J.L. et al. Sulphasalazine in psoriatic arthritis: a rondomized, multicentre, placebo-controlled study. BrJ.Rheumatol., 1996, 35, 664-668.</p><p>Conell W, Miller A. Treating inflammatory bowel disease during pregnance. Risks and safety of drug therapy. Drug Safety, 1999,4, 311-323.</p><p>Dougados М., Dijrmans B., Khan M. et al. Conventional treatments for ankylosing spondylitis. Ann. Rheum. Dis. 2002, 61,suppl. 111,40-50.</p><p>Dougados M. Sulfasalazine. In: Therapy of Systemic Rheumatic Disorders, van de Putte, LBA, Furst, DE, Williams, HJ, van Riel, PLCM, (Eds), Marcel Dekker, New York, 1998.</p><p>Dougados M, van der Linden S., Leirisalo-Repo M. et al. Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthr. Rheum., 1995, 38,618-627.</p><p>Egsmose C., Hansen Т., Andersen L.S. et al. Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann. Rheum. Dis., 1997, 56, 32-36.</p><p>Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J. Rheumatol., 1990,17,1482-1486.</p><p>Fraser S.M., Hopkins R., Hunter J.A. Sulphazalazine in the management of psoriatic arthritis. Br. J. Rheumatol., 1993, 32, 923-925.</p><p>Fuchs, H.A. Use of sulfasalazine in rheumatic diseases. Bull. Rheum. Dis., 1997, 46, 3.</p><p>Gladman D.D. Effictiveness of psoriatic arthritis. Sem. Arthr. Rheum., 2003, 33. 29-31.</p><p>Gupta A.K., Grober J.S., Hamilton T.A. et al. Sulphasalazine therapy for psoriatic arthritis: a double blind placebo controlled trial. J.Rheumatol., 1995, 22, 894-898.</p><p>Haagsma C.J., van Riel P.L., De Jong A.J., van de Putte L.B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br. J. Rheumatol., 1997,36,1082.</p><p>Hannoncn P., Mottinen Т., Hakola М., Oka M. Sulfasalazine in early rheumatoid arthritis: A 48 week double-blind prospective, placebo-controlled study. Arthr. Rheum. 1993,36,1501.</p><p>Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis. Cochrane Database Syst. Rev., 2000,3, CD000212.</p><p>Mottonen Т., Hannonen P. Leirisalo-Repo M. et al. Comparison of combination therapy with single in early rheumatoid arthritis. Lancet. 1999, 353, 1568-1573.</p><p>Nash P., Clegg D.O. Psoriatic arthritis therapy: NSAlDs and traditional DMARDs. Ann. Rheum. Dis., 2005,64, suppl. II, 7477.</p><p>О Dell J., Yaire S., Erikson N. et al. Triple DMARD therapy for rheumatoid arthritis is well tolerated. Arthr. Rheum., 1994, suppl. 10, 37.</p><p>Peppercorn M.A. Sulphasalazine: pharmacology, clinical use, toxicity and related new drug development. Ann. Intern. Med., 1984, 101,377-386.</p><p>Rahman P., Gladman D.D., Thome J.C. et al. The use sulphasalazine in psoriatic arthritis: a clinical experience. J. Rheumatol., 1998.25, 1957-1961.</p><p>Rains C.P., Noble S., Faulds D. Sulphasalazine. A review of its pharmacological properties and theraupetic efficacy in the treatment of rheumatoid arthritis. Drugs, 1995, 50, 137-156.</p><p>Rodenburg R.J., Ganga A., van Lent PL. et al. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthr, Rheum., 2000, 43. 1941.</p><p>SieperJ., Braun J., Rudwaleit M. et al. Ankylosing spondylitis: an overview. Ann. Rheum. Dis. 2002, 61, suppl. 111,8-18.</p><p>Salvarani C., Macchioni P., Olivieri I. et al. A comparison of cyclosporine, sulphasala-zine and symptomatic therapy in the treatment of psoriatic arthritis. J. Rheumatol., 2001, 28, 22742282.</p><p>SmolenJ.S., Kalden J.R., Scott D.L. etal. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet, 1999, 353. 259.</p><p>Taggard A.J., Gardiner P.V., Me Ewoy F.M. et al. Which is active moiety of sulphasalazine in ankylosing spondylitis? Arthr. Rheum., 1996, 39, 1400-1405.</p><p>Tanaka Е., Taniguchi A., Urano W. et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J. Rheumatol., 2002, 29, 2492.</p><p>&n der Heijde D.M., van Riel., P.L., Nuver-Zvart H.H., van de Putte L.B. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet, 1990, 335, 539.</p><p>Wahl C., Lipty S., Adler G., Schmid R.M. Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa Br. J. Clin. Invest., 1998, 101, 1163.</p><p>Wteinblatt M.E., Reda D., Henderson W. et al. Sulphasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J. Rheumatol., 1999, 26, 2123.</p></div><br />
Рецензия
Для цитирования:
Бадокин В.В. Эффективность и переносимость сульфасалазина при ревматических заболеваниях. Научно-практическая ревматология. 2005;43(4):47-52. https://doi.org/10.14412/1995-4484-2005-617
For citation:
Badokin V.V. Sulfasalazine efficacy and tolerability in rheumatic diseases. Rheumatology Science and Practice. 2005;43(4):47-52. (In Russ.) https://doi.org/10.14412/1995-4484-2005-617